Journal article
Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis.
Abstract
OBJECTIVE: The glucagon-like peptide-1 receptor agonist dulaglutide reduced MACE in the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. This article expores the relationship of selected biomarkers to both dulaglutide and major adverse cardiovascular events (MACE).
RESEARCH DESIGN AND METHODS: In this post hoc analysis, stored fasting baseline and 2-year plasma samples from 824 REWIND participants with MACE …
Authors
Gerstein HC; Lee S-F; Paré G; Bethel MA; Colhoun HM; Hoover A; Lakshmanan M; Lin Y; Pirro V; Qian H-R
Journal
Diabetes Care, Vol. 46, No. 5, pp. 1046–1051
Publisher
American Diabetes Association
Publication Date
May 1, 2023
DOI
10.2337/dc22-2397
ISSN
0149-5992